|1.||Carboni, Joan M: 7 articles (02/2015 - 12/2009)|
|2.||Gottardis, Marco M: 6 articles (01/2012 - 12/2009)|
|3.||Greer, Ann: 4 articles (02/2015 - 12/2009)|
|4.||Huang, Fei: 4 articles (02/2015 - 09/2010)|
|5.||Hillerman, Stephen: 3 articles (02/2015 - 12/2009)|
|6.||Hurlburt, Warren: 3 articles (02/2015 - 12/2009)|
|7.||Reeves, Karen A: 3 articles (02/2015 - 09/2010)|
|8.||Chang, Han: 2 articles (02/2015 - 09/2010)|
|9.||Helman, Lee J: 1 article (04/2015)|
|10.||Mendoza, Arnulfo: 1 article (04/2015)|
12/01/2009 - "Combination studies with BMS-754807 have been done on multiple human tumor cell types and showed in vitro synergies (combination index, <1.0) when combined with cytotoxic, hormonal, and targeted agents. "
01/01/2015 - "Pharmacokinetic analysis demonstrated that tumor tissue drug concentrations of BMS-754807 were well below the identified IC50, suggesting that inadequate drug delivery may limit in vivo efficacy. "
12/01/2012 - "BMS-754807 also caused a decrease in phospho-IGF-1R and phospho-AKT in tumor tissue lysates. "
04/15/2011 - "The IGF signature was present in triple-negative breast cancers (TNBC) and TNBC cell lines, which were especially sensitive to BMS-754807, and sensitivity was significantly correlated to the expression of the IGF gene signature. "
04/01/2011 - "In vivo BMS-754807 induced significant differences in EFS distribution compared to controls in 18 of 32 evaluable solid tumor xenografts (56%) tested, but in none of the ALL xenografts studied. "
09/15/2010 - "Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model."
09/15/2010 - "In light of this problem, we developed two resistant models from the rhabdomyosarcoma cell line Rh41: Rh41-807R, with acquired resistance to BMS-754807, a small-molecule dual-kinase inhibitor targeting IGF-IR and insulin receptor (IR), and Rh41-MAB391R, with resistance to MAB391, an IGF-IR-blocking antibody. "
04/01/2015 - "We showed that treatment with an IGF-IR antibody, R1507, or an IR/IGF-IR kinase inhibitor, BMS-754807, was associated with increased activation of YES/SRC family tyrosine kinase (SFK) in rhabdomyosarcoma (RMS). "
12/01/2009 - "BMS-754807 effectively inhibits the growth of a broad range of human tumor types in vitro, including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, gastric), and hematopoietic (multiple myeloma and leukemia) tumor cell lines (IC50, 5-365 nmol/L); the compound caused apoptosis in a human rhabdomyosarcoma cell line, Rh41, as shown by an accumulation of the sub-G1 fraction, as well as by an increase in poly ADP ribose polymerase and Caspase 3 cleavage. "
|3.||Breast Neoplasms (Breast Cancer)
01/01/2013 - "BRCA-MoNet was applied to three independent data sets obtained from the GEO database: Estrodial treated MCF7 cell line, BMS-754807 treated MCF7 cell line, and a breast cancer patient microarray dataset. "
12/15/2011 - "Overall, these results offer a preclinical proof-of-concept for BMS-754807 as an antitumor agent in combination with hormonal therapies in hormone-sensitive breast cancer. "
12/15/2011 - "Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer."
12/15/2011 - "Using a model of postmenopausal, estrogen-dependent breast cancer, we investigated the antitumor effects of the dual IGF-1R/InsR tyrosine kinase inhibitor BMS-754807 alone and in combination with letrozole or tamoxifen. "
|5.||Colorectal Neoplasms (Colorectal Cancer)
02/01/2015 - "This work proposed clinical development opportunities for BMS-754807 in colorectal cancer with patient selection to improve clinical benefit."
02/01/2015 - "Coupling in vitro sensitivity testing of BMS-754807, a dual IGF-1R/IR inhibitor, with genomic interrogations in 60 human colorectal cancer cell lines, we identified biomarkers correlated with response to BMS-754807. "
02/01/2015 - "IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines."
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|5.||Caspase 3 (Caspase-3)
|6.||IGF Type 1 Receptor (IGF 1 Receptor)
|7.||Biological Markers (Surrogate Marker)
|9.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
|10.||Insulin-Like Growth Factor I (IGF-1)
|1.||Heterologous Transplantation (Xenotransplantation)